The FDA has approved Novartis’ chimeric antigen receptor T cell (CAR-T) cell therapy, Kymriah (tisagenlecleucel, formerly CTL019), for the treatment of patients 25 years and younger with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. It is the first FDA-approved CAR-T immunotherapy, which uses specifically developed Cell Therapy Systems (CTS) Dynabeads technology, part of Thermo Fisher’s Cell Therapy Systems (CTS) portfolio. The magnet...